This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Feb;29(1):59-63.

doi: 10.1016/s0305-7372(02)00125-1.

Uracil/tegafur plus oral leucovorin does not affect survival rates but may be better tolerated than standard fluorouracil and leucovorin for previously untreated metastatic colorectal cancer

Affiliations

PMID: 12633582
DOI: 10.1016/s0305-7372(02)00125-1

Comment

Uracil/tegafur plus oral leucovorin does not affect survival rates but may be better tolerated than standard fluorouracil and leucovorin for previously untreated metastatic colorectal cancer

Borut Stabuc. Cancer Treat Rev. 2003 Feb.

. 2003 Feb;29(1):59-63.

doi: 10.1016/s0305-7372(02)00125-1.

Author

Affiliation

¹ Department of Gastroenterology, University Medical Center Ljubljana, Slovenia. borut.stabuc@kclj.si

PMID: 12633582
DOI: 10.1016/s0305-7372(02)00125-1

No abstract available

PubMed Disclaimer

Comment on

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE. Douillard JY, et al. J Clin Oncol. 2002 Sep 1;20(17):3605-16. doi: 10.1200/JCO.2002.04.123. J Clin Oncol. 2002. PMID: 12202661 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science